Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omiganan in mild to moderate atopic dermatitis
NCT03091426Phase 2Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omiganan in atopic dermatitis (AD) (4 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Objective SCORing Atopic Dermatitis at 7 weeks, Eczema Area and Severity Index at 7 weeks and 12 more. Started Mar 2017; status: completed.
02
Drugs
omiganan
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03091426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091426.